Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 95 SAWYER ROAD, SUITE 110 WALTHAM MA 02453 |
Tel: | 1-617-4307577 |
Website: | https://checkpointtx.com |
IR: | See website |
Key People | ||
Michael S. Weiss Chairman of the Board | James F. Oliviero President, Chief Executive Officer, Director | William Garrett Gray Chief Financial Officer, Treasurer, Corporate Secretary |
Business Overview |
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company that is focused on the acquisition, development and commercialization of treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, which is an anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute (Dana-Farber) in an ongoing global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) intended to support one or more applications for marketing approval. In addition, it is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, which is an epidermal growth factor receptor (EGFR) inhibitor as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). |
Financial Overview |
For the fiscal year ended 31 December 2023, Checkpoint Therapeutics Inc revenues decreased 46% to $103K. Net loss decreased 17% to $51.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development decrease of 13% to $42.4M (expense), Gain (loss) on common stock warrant liab increase from $4.5M (expense) to $217K (income). |
Employees: | 23 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $67.87M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.10M as of Dec 31, 2023 |
EBITDA (TTM): | -$52.15M as of Dec 31, 2023 |
Net annual income (TTM): | -$51.85M as of Dec 31, 2023 |
Free cash flow (TTM): | -$47.59M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 35,686,279 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |